Influence of mesenchymal stem cells from different origins on the therapeutic effectiveness of systemic lupus erythematosus

被引:0
作者
Yuan, Yuan [1 ]
Liu, Tong [1 ]
机构
[1] Univ South China, Hengyang Med Coll, Hengyang 421001, Hunan, Peoples R China
关键词
Mesenchymal stem cells; Systemic lupus erythematosus; Clinical trials; Heterogeneity; BONE-MARROW; STROMAL CELLS; B-CELLS; INTERNATIONAL-SOCIETY; INTERFERON-BETA; MURINE MODEL; T-CELLS; TISSUE; TRANSPLANTATION; TH17;
D O I
10.1016/j.yexcr.2024.114263
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Systemic Lupus Erythematosus (SLE) is a chronic autoimmune inflammatory disorder characterized by ations in the balance between inflammatory and regulatory cytokines. Mesenchymal stem cells (MSCs), which are non-hematopoietic stem cells with multipotent differentiation potential, due to their immunomodulatory, tissue repair, low immunogenicity, and chemotactic properties, have garnered increasing interest in SLE ment. Studies increasingly reveal the heterogeneous nature of MSC populations. With sources including dental pulp, adipose tissue, bone marrow, and umbilical cord, the therapeutic effects of MSCs on SLE vary depending their origin. This review consolidates clinical research on MSCs from different sources in treating SLE and alyzes the possible causes underlying these variable outcomes. Additionally, it elucidates five potential factors impacting the outcomes of MSC therapy in SLE: the influence of the microenvironment on MSCs, the complexity and paradoxical aspects of MSC mechanisms in SLE treatment, the heterogeneity of MSCs, the in vivo differentiation potential and post-transplant survival rates of MSCs, and disparities in MSC preparation conditions.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Galectin-1-producing mesenchymal stem cells restrain the proliferation of T lymphocytes from patients with systemic lupus erythematosus
    Xiong, Hui
    Li, Chijun
    Tang, Zengqi
    Ma, Jianchi
    Tan, Guozhen
    Luo, Yijin
    Guo, Zhixuan
    Guo, Qing
    IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, 2024, 46 (05) : 618 - 626
  • [32] Human Umbilical Cord Mesenchymal Stem Cells for the Treatment of Systemic Lupus Erythematosus via Glucose Metabolism of CD4+T Cells
    Ding, Meng
    Jin, Lu
    Cui, Shaoxin
    Yang, Lin
    He, Jingjing
    Wang, Xiaoping
    Chang, Fei
    Wang, Qun
    Liu, Xue
    Jin, Hongtao
    Song, Shuran
    Shi, Min
    Yu, Jingjing
    Ma, Jun
    Liu, Aijing
    STEM CELL REVIEWS AND REPORTS, 2025, : 1013 - 1033
  • [33] Effects of human umbilical cord mesenchymal stem cells on inflammatory factors and miR-181a in T lymphocytes from patients with systemic lupus erythematosus
    Zheng, B.
    Zhang, P.
    Yuan, L.
    Chhetri, R. K.
    Guo, Y.
    Deng, D.
    LUPUS, 2020, 29 (02) : 126 - 135
  • [34] Mesenchymal stem cells originating from ES cells show high telomerase activity and therapeutic benefits
    Ninagawa, Nana
    Murakami, Rumi
    Isobe, Eri
    Tanaka, Yusuke
    Nakagawa, Hiroki
    Torihashi, Shigeko
    DIFFERENTIATION, 2011, 82 (03) : 153 - 164
  • [35] Therapeutic Potential of Wharton's Jelly Mesenchymal Stem Cells for Diabetes: Achievements and Challenges
    Kamal, Mohamed M.
    Kassem, Dina H.
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2020, 8
  • [36] Double Allogenic Mesenchymal Stem Cells Transplantations Could Not Enhance Therapeutic Effect Compared with Single Transplantation in Systemic Lupus Erythematosus
    Wang, Dandan
    Akiyama, Kentaro
    Zhang, Huayong
    Yamaza, Takayoshi
    Li, Xia
    Feng, Xuebing
    Wang, Hong
    Hua, Bingzhu
    Liu, Bujun
    Xu, Huji
    Chen, Wanjun
    Shi, Songtao
    Sun, Lingyun
    CLINICAL & DEVELOPMENTAL IMMUNOLOGY, 2012,
  • [37] Modulation of Mesenchymal Stem Cells-Mediated Adaptive Immune Effectors’ Repertoire in the Recovery of Systemic Lupus Erythematosus
    Akram Hoseinzadeh
    Zahra Rezaieyazdi
    Jalil Tavakol Afshari
    Ali Mahmoudi
    Sahar Heydari
    Reza Moradi
    Seyed-Alireza Esmaeili
    Mahmoud Mahmoudi
    Stem Cell Reviews and Reports, 2023, 19 : 322 - 344
  • [38] Autologous mesenchymal stem cell treatment increased T regulatory cells with no effect on disease activity in two systemic lupus erythematosus patients
    Carrion, F.
    Nova, E.
    Ruiz, C.
    Diaz, F.
    Inostroza, C.
    Rojo, D.
    Monckeberg, G.
    Figueroa, F. E.
    LUPUS, 2010, 19 (03) : 317 - 322
  • [39] Characterization and Therapeutic Application of Mesenchymal Stem Cells with Neuromesodermal Origin from Human Pluripotent Stem Cells
    Wang, Huiyan
    Li, Dairui
    Zhai, Zhichen
    Zhang, Xiaoran
    Huang, Weijun
    Chen, Xiaoyong
    Huang, Lihua
    Liu, Huanyao
    Sun, Jiaqi
    Zou, Zhengwei
    Fan, Yubao
    Ke, Qiong
    Lai, Xingqiang
    Wang, Tao
    Li, Xiaoping
    Shen, Huiyong
    Xiang, Andy Peng
    Li, Weiqiang
    THERANOSTICS, 2019, 9 (06): : 1683 - 1697
  • [40] Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study
    Liang, Jun
    Zhang, Huayong
    Hua, Bingzhu
    Wang, Hong
    Lu, Liwei
    Shi, Songtao
    Hou, Yayi
    Zeng, Xiaofeng
    Gilkeson, Gary S.
    Sun, Lingyun
    ANNALS OF THE RHEUMATIC DISEASES, 2010, 69 (08) : 1423 - 1429